June 3rd, 2020
June 2nd, 2020
May 31st, 2020
May 25, 2020
April 22, 2020
March 12, 2020
SaNOtize closes a $1M investment from OurCrowd, the most active Israeli venture investor.
February 25, 2020
SaNOtize is honoured to welcome Ferid Murad, M.D., Ph.D. to the SaNOtize board of directors. Dr. Murad was awarded the 1998 (along with Robert F. Furchgott and Louis J. Ignarro) Nobel Prize in Physiology or Medicine for the discovery that nitric oxide acts as a signalling molecule in the cardiovascular system. Their combined work uncovered an entirely new mechanism for how blood vessels in the body relax and widen.
December 30, 2019
SaNOtize was awarded $1.2M from the US Department Of Defence (U.S. Army Medical Research Acquisition Activity) to help fund a phase I clinical trial to evaluate the use of their product for treatment of diabetic foot ulcer.
November 28, 2019
First patient enrolled into chronic sinusitis Phase II clinical trial.
SaNOtize received a “No Objection Letter” from Health Canada to proceed with a phase II clinical trial to evaluate the use of their product for treatment of chronic sinusitis.
SaNOtize received a “No Objection Letter” from Health Canada to proceed with a phase I clinical trial to evaluate the use of their product for treatment of diabetic foot ulcer.
SaNOtize was one of ten companies selected to be on the 2019 “Ready to Rocket” list.
SaNOtize has secured a $450,000 USD lead investment for its $1,500,000 seed-stage financing. The funding was directed by M.Y. Capital Management, a registered investment management firm in Canada. The proceeds of this investment will be used to complete a phase IIa trial in chronic sinusitis and onychomycosis, and to develop a device prototype for onychomycosis.
SaNOtize enrolled its first patient into the chronic sinusitis dose escalation clinical trial at St. Paul’s hospital, Vancouver, BC.
SaNOtize partners with SPIRE Bioventures to enhance it’s profile in the San Francisco Bay area bio-tech and investor communities. SaNOtize is commercializing its NORS platform technology and seeking strategic and financial partners to accelerate its growth.
The SPIRE Bioventures mentors are dedicated equity partners who work together in a closed network, serving companies as international consultants, advisors and board members. Spire Bioventures facilitates key transitions across a company’s lifecycle.
SaNOtize received a “No Objection Letter” from Health Canada to proceed with a clinical trial in chronic sinusitis. The trial will begin enrolling patients in Nov 2018.
SaNOtize received an Industrial Research Assistance Program (IRAP) grant to develop a drug-device combination to treat Onychomycosis.
SaNOtize is selected as a finalist for the Innovation Challenge at the RESI conference in Boston on September 6, 2018.
SaNOtize has received a 200K USD investment from an angel investor.
SaNOtize will be presenting at the Biotech Showcase™ Annual Conference on January 10th 2018
[Vancouver, Dec 20th 2017] –SaNOtize’s CEO, Dr. Gilly Regev, today announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Dr. Regev, CEO, will present at the Biotech Showcase™ as follows:
Date: 10th, January , 2018
Time: 9:15am (PST)
Room: Franciscan B
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
SaNOtize, based in Vancouver BC, was incorporated,as a clinical stage biotech startup, to commercialize the multi-faceted antimicrobial properties of a liquid producing nitric oxide. We have developed and patented a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections.
The co-founders, have vast scientific and clinical expertise, specifically in nitric oxide, as well as regulatory, IP and management experience. We have successfully brought nitric oxide based drugs & devices to mid- phase 2 and negotiated and completed single-asset pharmaceutical agreements.
SaNOtize is using nitric oxide, a natural molecule to our body, to treat topical infections. In fact, NO is part of our body’s own defence mechanism against infections. Unlike antibiotic, NO, can eradicate bacteria, viruses, fungi and all drug resistant bugs. On top of that, it is a vasodilator, involved in wound healing and modulates inflammation.
We have succeeded in finding the way to produce and deliver NO at an antimicrobial concentration and have an issued patent on the methods and composition.
We have decided to start with Athlete’s Foot as our first indication as it is a relatively simple disease, low cost of clinical trials and has significant advantages over the current practice. We have completed phase I clinical trial with a NOL from Health Canada and showed safety and efficacy with no adverse events. Other indication on our platform technology varies from a foot bath for DFU through strep throat gargle to a nasal spray for flu prevention.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that SaNOtize will be [presenting] at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Additional links and information:
Follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton – #BiotechShowcase